NO20042284L - Sulfatkonjugater av ursodeoksycholinsyre og deres fordelaktige anvendelser ved inflammatoriske forstyrrelser og andre anvendelser - Google Patents

Sulfatkonjugater av ursodeoksycholinsyre og deres fordelaktige anvendelser ved inflammatoriske forstyrrelser og andre anvendelser

Info

Publication number
NO20042284L
NO20042284L NO20042284A NO20042284A NO20042284L NO 20042284 L NO20042284 L NO 20042284L NO 20042284 A NO20042284 A NO 20042284A NO 20042284 A NO20042284 A NO 20042284A NO 20042284 L NO20042284 L NO 20042284L
Authority
NO
Norway
Prior art keywords
udca
sulfate
tauro
disulfate
glyco
Prior art date
Application number
NO20042284A
Other languages
English (en)
Other versions
NO20042284D0 (no
Inventor
Kenneth D R Setchell
Original Assignee
Childrens Hosp Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hosp Medical Center filed Critical Childrens Hosp Medical Center
Publication of NO20042284D0 publication Critical patent/NO20042284D0/no
Publication of NO20042284L publication Critical patent/NO20042284L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO20042284A 1995-11-21 2004-06-02 Sulfatkonjugater av ursodeoksycholinsyre og deres fordelaktige anvendelser ved inflammatoriske forstyrrelser og andre anvendelser NO20042284L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/560,992 US5763435A (en) 1995-11-21 1995-11-21 Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders
PCT/US1996/018487 WO1997018816A2 (en) 1995-11-21 1996-11-19 Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders and other applications

Publications (2)

Publication Number Publication Date
NO20042284D0 NO20042284D0 (no) 2004-06-02
NO20042284L true NO20042284L (no) 2004-06-02

Family

ID=24240215

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19982281A NO317063B1 (no) 1995-11-21 1998-05-19 Anvendelse av UDCA (ursodeoksycholinsyre) for forebyggelse og behandling av leversykdom hos pattedyr
NO20042284A NO20042284L (no) 1995-11-21 2004-06-02 Sulfatkonjugater av ursodeoksycholinsyre og deres fordelaktige anvendelser ved inflammatoriske forstyrrelser og andre anvendelser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19982281A NO317063B1 (no) 1995-11-21 1998-05-19 Anvendelse av UDCA (ursodeoksycholinsyre) for forebyggelse og behandling av leversykdom hos pattedyr

Country Status (15)

Country Link
US (2) US5763435A (no)
EP (1) EP0871452B1 (no)
JP (3) JP3836148B2 (no)
KR (1) KR19990071521A (no)
CN (2) CN100556408C (no)
AT (1) ATE397450T1 (no)
AU (1) AU709594B2 (no)
BR (1) BR9611606A (no)
CA (1) CA2238040C (no)
DE (1) DE69637556D1 (no)
EA (1) EA199800399A1 (no)
NO (2) NO317063B1 (no)
NZ (1) NZ323274A (no)
PL (1) PL186393B1 (no)
WO (1) WO1997018816A2 (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046185A (en) * 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
DE19645044A1 (de) * 1996-10-31 1998-05-07 Falk Pharma Gmbh Verwendung von Ursodeoxycholsäure zur topischen Behandlung von Entzündungserkrankungen der Schleimhäute
RU2224523C2 (ru) * 1998-07-24 2004-02-27 Сео Хонг Ю Водный раствор, содержащий желчную кислоту, и способ его получения
DE19906290A1 (de) * 1999-02-15 2000-08-17 Falk Pharma Gmbh Arzneimittel zur Behandlung bzw. Prävention von Darmkrebs
EP1158989B1 (en) * 1999-03-09 2007-06-20 Anker, Stefan Use of inhibitors of endotoxin for the treatment of cachexia
EP1284723A4 (en) * 2000-04-19 2004-06-30 Borody Thomas J COMPILATIONS AND THERAPIES FOR HYPERLIPIDEMIA-ASSOCIATED DISEASES
US6596762B2 (en) 2001-05-17 2003-07-22 The Regents Of The University Of Colorado Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
FR2829697B1 (fr) * 2001-09-14 2004-03-19 Mayoly Spindler Lab Derives 7-hydroxyles et 7-cetoniques des hormones steroides 3 beta-hydroxylees pour le traitement des maladies inflammatoires ou fonctionnelles de l'intestin
ITTO20020102A1 (it) * 2002-02-06 2003-08-06 Abc Ist Biolog Chem Spa Procedimento per la preparazione dell'acido ursodesossicolico disolfato e suoi sali farmaceuticamente accettabili.
CN100421656C (zh) * 2002-11-07 2008-10-01 明尼苏达大学评议会 乌索脱氧胆酸在制备治疗与出血相关的神经系统损伤的药物中的用途
ITMI20030822A1 (it) * 2003-04-18 2004-10-19 Erregierre Spa Processo per la preparazione dell'acido ursodesossicolico
EP2182856A2 (en) 2007-08-08 2010-05-12 Brian J. Cavanaugh Method and apparatus for delivery of a ligating suture
EP2208497A1 (en) * 2009-01-15 2010-07-21 Charité-Universitätsmedizin Berlin (Charité) Use of Ursodeoxycholic acid (UDCA) for enhancing the general health condition of a tumor patient
IT1393095B1 (it) 2009-02-19 2012-04-11 Prodotti Chimici Alimentari Processo per la sintesi del sale disodico dell'acido ursodesossicolico 3,7-disolfato.
CN102656153B (zh) 2009-10-29 2015-02-18 延世大学校产学协力团 新型血管渗漏阻断剂
US20130011413A1 (en) * 2010-02-03 2013-01-10 The University Of Tokyo Method and Pharmaceutical Composition for Treatment of Intestinal Disease
WO2013025840A1 (en) 2011-08-15 2013-02-21 Massachusetts Eye And Ear Infirmary Methods for preserving photoreceptor cell viability following retinal detachment
KR101953298B1 (ko) * 2017-07-18 2019-02-28 의료법인 성광의료재단 우르소데옥시콜산을 함유하는 염증성 질환 또는 척수 손상 예방 또는 치료용 조성물
US12186329B2 (en) 2018-08-23 2025-01-07 President And Fellows Of Harvard College Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes
EP3890745B1 (en) 2018-12-04 2025-11-19 President and Fellows of Harvard College Synthetic derivatives of cholic acid 7-sulfate and uses thereof
KR20250171471A (ko) 2019-05-10 2025-12-08 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 장 박테리아 담즙산 대사의 소분자 조정제
WO2020242744A1 (en) * 2019-05-31 2020-12-03 Metabolon, Inc. Mass spectrometry assay methods for detection of metabolites
JP2022544239A (ja) 2019-08-12 2022-10-17 マサチューセッツ インスティテュート オブ テクノロジー 治療薬の投与のための物品及び方法
WO2025130826A1 (en) * 2023-12-18 2025-06-26 Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences Compositions and methods for treating cancer
CN117949648B (zh) * 2024-03-26 2024-07-12 中国医学科学院北京协和医院 一种用于检测溃疡性结肠炎的标志物及用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1221734B (it) * 1983-02-24 1990-07-12 Schiena Michele Giuseppe Di Ursodesossicolico solfato acido sale sodico
US5460812A (en) * 1992-06-22 1995-10-24 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof

Also Published As

Publication number Publication date
ATE397450T1 (de) 2008-06-15
JP4630195B2 (ja) 2011-02-09
WO1997018816A2 (en) 1997-05-29
KR19990071521A (ko) 1999-09-27
CA2238040C (en) 2004-07-13
PL326931A1 (en) 1998-11-09
CA2238040A1 (en) 1997-05-29
US6251884B1 (en) 2001-06-26
US5763435A (en) 1998-06-09
WO1997018816A3 (en) 1997-06-26
AU7737796A (en) 1997-06-11
CN100556408C (zh) 2009-11-04
EP0871452A2 (en) 1998-10-21
JP3836148B2 (ja) 2006-10-18
BR9611606A (pt) 2000-10-24
NO317063B1 (no) 2004-08-02
AU709594B2 (en) 1999-09-02
JP2000500764A (ja) 2000-01-25
JP5277221B2 (ja) 2013-08-28
NO20042284D0 (no) 2004-06-02
DE69637556D1 (de) 2008-07-17
CN101569632A (zh) 2009-11-04
EP0871452B1 (en) 2008-06-04
JP2006117698A (ja) 2006-05-11
EA199800399A1 (ru) 1998-12-24
MX9803988A (es) 1998-10-31
JP2011006445A (ja) 2011-01-13
NO982281D0 (no) 1998-05-19
PL186393B1 (pl) 2004-01-30
CN1211185A (zh) 1999-03-17
NZ323274A (en) 2000-07-28
NO982281L (no) 1998-07-08

Similar Documents

Publication Publication Date Title
NO20042284D0 (no) Sulfatkonjugater av ursodeoksycholinsyre og deres fordelaktige anvendelser ved inflammatoriske forstyrrelser og andre anvendelser
Liu et al. Probiotic Lactobacillus rhamnosus GG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice
Kojima et al. Comparative effects of three chelating agents on distribution and excretion of cadmium in rats
Zhang et al. Stigmasterol attenuates hepatic steatosis in rats by strengthening the intestinal barrier and improving bile acid metabolism
Aizawa et al. Different effects of angiotensin II and catecholamine on renal cell apoptosis and proliferation in rats
BRPI0206641B8 (pt) uso de um inibidor da absorção de esteróis
BR9909908A (pt) Derivados de ácidos graxos de ácidos biliares e derivados de ácidos biliares
NO992936L (no) Fremgangsmåte for å behandle nyresvikt
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
BRPI0412885A (pt) polipeptìdios, agentes de ligação especìficos, moléculas de ácido nucleico e linhas de células isoladas, células hospedeiras, composições e anticorpo ou domìnio de ligação de antìgeno e métodos de tratamento de cáncer e de tumor sólido num paciente, de detecção do nìvel do fator de crescimento hepatócito (hgf) numa amostra, de obtenção de anticorpo e de inibição da ligação de hgf a met e de diminuição ou prevenção da ligação de qualquer um dos agentes de ligação especìficos ao fator de crescimento hepatócito (hgf)
UY27438A1 (es) Composición farmaceútica que comprende un conjugado oligómero-farmaco insulina, método para tratar deficiencia de insulina en un sujeto, método para proveer una composición farmacéutica.
Seo et al. Co-administration of ursodeoxycholic acid with rosuvastatin/ezetimibe in a non-alcoholic fatty liver disease model
Zimber et al. Functional interactions between bile acids, all-trans retinoic acid, and 1, 25-dihydroxy-vitamin D3 on monocytic differentiation and myeloblastin gene down-regulation in HL60 and THP-1 human leukemia cells
ATE271547T1 (de) Pyridazinone als inhibitoren von cyclooxygenase-2
Wollina et al. Treatment of recalcitrant ulcers in pyoderma gangrenosum with mycophenolate mofetil and autologous keratinocyte transplantation on a hyaluronic acid matrix
Kobylinska et al. Biochemical indicators of hepatotoxicity in blood serum of rats under the effect of novel 4-thiazolidinone derivatives and doxorubicin and their complexes with polyethyleneglycol-containing nanoscale polymeric carrier
Li et al. IL-6 downregulates hepatic carboxylesterases via NF-κB activation in dextran sulfate sodium-induced colitis
Van Molle et al. Protection of zinc against tumor necrosis factor–induced lethal inflammation depends on heat shock protein 70 and allows safe antitumor therapy
Goyal et al. Bacosides encapsulated in lactoferrin conjugated PEG-PLA-PCL-OH based polymersomes act as epigenetic modulator in chemically induced amnesia
Di Leo et al. Effect of zinc supplementation on trace elements and intestinal metallothionein concentrations in experimental colitis in the rat
Schröder et al. Xylocaine treatment in experimental pancreatitis in pigs
Jo et al. Bile acid-based polydrug nanoparticles for the treatment of acute liver injury
Morris et al. Regulation of plasma levels of aldosterone and its metabolites during the latent period of aldosterone
CN112007038B (zh) 血红素氧合酶-1诱导剂及其应用
Vecchio et al. Faecal elimination of steroids in rats after oral administration of mepartricin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application